News
科思
Homepage
/
News
/
Company News
/
Our company's patent application for vascular stent structure design has been authorized by the State Intellectual Property Office for invention patents

Our company's patent application for vascular stent structure design has been authorized by the State Intellectual Property Office for invention patents

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2020-07-07 09:16
  • Views:

(Summary description)Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

Our company's patent application for vascular stent structure design has been authorized by the State Intellectual Property Office for invention patents

(Summary description)Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2020-07-07 09:16
  • Views:
Information

Our company's patent application for the structural design of vascular stent, "A stent with an obturator structure, its preparation method and use", was officially authorized by the State Intellectual Property Office of China on June 30, 2020. Patent number ZL201580079706.4. Our company's 3D printed fully degradable coronary stent, AMSorb®, adopts this structural design and has entered the clinical trial stage. The U.S. patent application for this patent was granted an invention patent by the U.S. Patent Office in March 2020.

The structural design of vascular stent is one of the important factors affecting the clinical effect of vascular stent. The structural design of the stent directly affects the radial support force, hemodynamics, delivery and adherence of the stent.

Previous: [CCI Innovation Weekly News] Abbott Restarts Clinical Trial of Bioresorbable Stent, Novel Esprit Below-Knee Stent
Next: Amet withdrew the application for clinical trial approval of "Fully degradable peripheral vascular drug-eluting stent system", and will resubmit after further improvement of the application materials
Previous: [CCI Innovation Weekly News] Abbott Restarts Clinical Trial of Bioresorbable Stent, Novel Esprit Below-Knee Stent
Next: Amet withdrew the application for clinical trial approval of "Fully degradable peripheral vascular drug-eluting stent system", and will resubmit after further improvement of the application materials
PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
2021 12-25

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment

This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
See more information
查看详情
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
2021 12-03

Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises

On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
See more information
查看详情
Beijing Amet was recognized as a "specialized, special and new" enterprise
2021 12-02

Beijing Amet was recognized as a "specialized, special and new" enterprise

On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.
See more information
查看详情

Company Information

Beijing Advanced Medical Technologies,Ltd.Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel：010-6297-7955           E-Mail：amt@ametcorp.com